BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company dedicated to developing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced today that its management will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026 in New York City.
Hernan Levett, Chief Financial Officer of BioVersys, will deliver a live presentation on September 16, 2026, from 12:30 PM to 1:00 PM ET at the Kennedy II room on the 4th floor of the Lotte New York Palace. In addition, Dr. Marc Gitzinger, Chief Executive Officer, will provide an on-demand presentation available live on September 11, 2026, at 7:00 AM ET, with a replay accessible for 90 days via the H.C. Wainwright platform or the BioVersys website in the investor section.
The company's participation in this prominent investment conference underscores its commitment to advancing its pipeline of innovative antibacterial therapies addressing the pressing global health threat of antimicrobial resistance. BioVersys leverages its proprietary TRIC and Ansamycin Chemistry platforms to design candidates that overcome resistance mechanisms, block virulence production, and directly target pathogenic bacteria, aiming to provide new treatment options in the antimicrobial and microbiome fields.
The most advanced programs include BV100, a Phase 3 candidate for nosocomial infections caused by Acinetobacter baumannii, and alpibectir, a Phase 2 candidate for tuberculosis developed in collaboration with GlaxoSmithKline (GSK) and a consortium led by the University of Lille, France. These programs represent significant strides toward addressing the high unmet medical need for effective treatments against resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders.
Presenting at the H.C. Wainwright conference provides BioVersys with a platform to communicate its strategic vision, recent achievements, and future milestones to a global audience of investors and industry stakeholders. The opportunity for one-on-one meetings with the CEO and CFO during the conference allows for in-depth discussions about the company's progress and potential.
As antimicrobial resistance continues to escalate worldwide, the development of novel therapeutics is critical. BioVersys's focus on overcoming resistance mechanisms and targeting pathogenesis positions it at the forefront of this fight. The company's participation in this conference is not just a routine corporate update; it is a signal of its readiness to engage with the financial community and advance its mission to bring life-saving treatments to patients.
For more information about BioVersys and its pipeline, interested parties can visit the company's website at www.bioversys.com. The on-demand presentation will be accessible via the H.C. Wainwright platform or the BioVersys website in the investor section.
